Anti-TNFα therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes

Autoimmunity Reviews

Volumn 8, Issue 3, 2009, Pages 260-265

  Bazzani, Chiara ^a   Filippini, Matteo ^a   Caporali, Roberto ^b   Bobbio Pallavicini, Francesca ^b   Favalli, Ennio Giulio ^c   Marchesoni, Antonio ^c   Atzeni, Fabiola ^d   Sarzi Puttini, Piercarlo ^d   Gorla, Roberto ^a  

^a Rheumatology and Clinical Immunology Unit   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti TNF alpha treatment; Biological drugs; Disease outcomes; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; CORTICOSTEROID; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; DISEASE ACTIVITY; DRUG COMBINATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; STEROID THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ACTIVE IMMUNIZATION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG INTERACTION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; ITALY; MIDDLE AGED; QUESTIONNAIRE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; ITALY; MALE; MIDDLE AGED; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149476778     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.11.001     Document Type: Review

References (19)

1. Van der Heijde D.M. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 34 Suppl. 2 (1995) 74-78
2. Mullan R.H., and Bresnihan B. Disease-modifying anti rheumatic drug therapy and structural damage in early rheumatoid arthritis. Clin Exp Rheumatol 21 (2003) S158-S164
3. Sesin C.A., and Bingham III C.O. Remission in rheumatoid arthritis: wishful thinking or clinical reality?. Semin Arthritis Rheum 35 (2005) 185-196
4. Pincus T., Kavanaugh A., Aletaha D., and Smolen J. Complexities in defining remission in rheumatic disease. Clin Exp Rheumatol 24 suppl. 43 (2006) S1-S6
5. Van Riel P. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 59 Suppl I (2000) i28-i31
6. Van Gestel A.M., Prevoo M.L.L., van't Hof M.A., et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 39 (1996) 34-40
7. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
8. Sarzi-Puttini P, Antivalle M, Marchesoni A, Favalli EG, Gorla R, Fillipini M, et al. Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN). Reumatismo 2008 in press.
9. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
10. Valesini G., Montecucco C., and Cutolo M. Anti-TNF treatment for rheumatoid arthritis. Clin Exp Rheum 4 (2006) 414-423
11. Prevoo M.L.L., Van't Hoff M.A., Kuper H.H., Van Leeuwen M.A., Van de Putte L.B.A., and Van Riel P.L.C.M. Modified Disease Activity Scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
12. Cruyssen B.V., Van Looy S., Wyns B., Westhovens R., Durez P., Van den Bosch F., et al. DAS28 best reflects the physician's clinical judgement of response to infliximab therapy in rheumatoid arthritis patients: validation of DAS28 score in patients under infliximab treatment. Arthritis Res Therapy 7 (2005) 1063-1071
13. Frensen J., and van Riel P.L. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23 Suppl. 39 (2005) S93-99
14. Ranza R., Marchesoni A., Calori G., Bianchi G., Braga M., Canazza S., et al. The Italian version of the functional disability index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies in rheumatoid arthritis. Clin Exp Rheumatol 11 (1993) 123-128
15. Kosinski M., Zhao S.Z., Dedhiya S., Osterhaus J.T., and Ware Jr. J.E. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 43 (2000) 1478-1487
16. Hyrich K.L., Watson K.D., Silman A.J., and Symmons D.P. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45 (2006) 1558-1565
17. Welsing P.M., van Gestel A.M., Swinkels H.L., Kiemeney L.A., and van Riel P.L. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44 (2001) 2009-2017
18. Chan A.T., Flossmann O., Mukhtyar C., Jayne D.R., and Luqmani R.A. The role of biologic therapies in the management of systemic vasculitis. Autoimmun Rev 5 (2006) 273-278
19. Puppo F., Murdaca G., Ghio M., and Indiveri R. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 4 (2005) 537-541